IBBME alumni’s startup seeks to improve cosmetic and mental outcomes for women with breast cancer

Soror Sharifpoor, IBBME PhD 1T1

IBBME alumna Soror Sharifpoor is the CEO and co-founder of Polumiros, which is developing a polymer to fill the cavities left in breast cancer patients following a lumpectomy. (Photo by Laura Pedersen).

February 23, 2018 | By Chris Sorensen

Rosane Brambilla Reis was a 37-year-old mother of two when a trip to the doctor’s office turned her life upside down.

She walked in with an apparent cyst in her breast. She left a cancer patient facing surgery, radiation and chemotherapy – not to mention long odds.

“I was an immigrant with a good job and then, all of a sudden, ‘boom,’” recalls the Brazil-born Brambilla Reis, now 67.

While Brambilla Reis was eventually declared cancer free, she remains physically, if not emotionally, scarred by the experience. She considered having reconstructive surgery, but ultimately decided she’d had enough invasive treatments to last a lifetime.

But what if cancer survivors were spared such difficult decisions in the first place?

Soror Sharifpoor (IBBME PhD 1T1) believes she has the answer. Through her startup Polumiros, co-founded with alumnus Kyle Battiston (IBBME PhD 1T5), they are developing a unique polymer surgeons can use to fill the void in breast tissue immediately following a lumpectomy procedure. The polymer, called ReFilx (short for regenerative filler matrix), acts as a temporary scaffold to support new tissue growth before dissolving harmlessly away into the body.

“The patients don’t have to go under the knife a second time,” says Sharifpoor, who is also the research program manager at the Ted Rogers Centre for Heart Research’s translational biology and engineering program.

“They never have to live with a defect.”

Such a procedure would not only improve the mental and emotional well-being of breast cancer patients, argues Sharifpoor, it could also encourage surgeons to take more aggressive margins around a tumour, thereby reducing the chances of cancer recurrence.

“That’s something we haven’t proven in humans yet, but is something we anticipate will be an outcome,” she says.

For Sharifpoor, she did her PhD in vascular tissue engineering – “We have a lot of heart problems in my family – especially on my father’s side” – and spent a lot of time working on polymers in the lab of U of T professor Paul Santerrean entrepreneurially minded researcher who has appointments in the Faculty of Dentistry and the Institute of Biomaterials & Biomedical Engineering. Then, one day, a surgical oncologist approached Santerre’s lab in search of a reconstructive material to be used on his lumpectomy patients, who were being given few options. As luck would have it, Sharifpoor and Battiston had a polymer originally developed for a cardiac application that potentially fit the bill – albeit with a few key tweaks.

“We started adjusting the chemistry and made the polymer softer so you won’t feel it once it’s implanted,” says Sharifpoor. “We also made it degradable so that it slowly dissolves over time, allowing the cells and tissues to infiltrate.

“It works really well and you can’t even feel it when implanted in living tissues.”

Yet, despite the promise ReFilx holds for millions of breast cancer patients, Polumiros’s path to market remains equal parts long and risky.

ReFilx polymer by Polumiros

ReFilx, a polymer, acts as a temporary scaffold that supports new tissue growth before dissolving harmlessly away into the body (photo by Laura Pedersen).

Founded two years ago, Polumiros is just now wrapping up its third round of pre-clinical trials on ReFilx. By this summer, the plan is to repeat the trials with a certified research organization so Polumiros can get the necessary regulatory approvals to conduct clinical trials. Sharifpoor is currently targeting a date of 2023 or 2024 for commercialization – assuming, of course, she and Battiston can raise the necessary $25 million from investors.

Contrast that to the experience of other startups who can build a nifty smartphone app to share photos or hail a taxicab in a few months with a seed investment of a few thousand dollars.

“When we do pitches at competitions and we’re competing with other entrepreneurs developing apps, we’re so far away when it comes to our timelines and the seed funding we need” says Sharifpoor.

“But I keep going back to what my supervisor [Santerre] said: ‘high risk, high reward.’ So we know this is high-risk, but we also know the end result could have a significant impact on patients in Canada and around the world.”

Santerre, for his part, says Sharifpoor “has entrepreneurship blood in her” and credits her for getting the idea off the ground before leaving his research group.

“She has a ‘let’s get it done, and let’s do it right’ attitude to tasks, which is a great attribute in the startup world,” Santerre says.

Fortunately, startups like Polumiros also have an expansive support network at U of T – and Toronto more broadly – to help them navigate the myriad hurdles associated with building a successful health-care business.

Sharifpoor says she’s received support from three U of T accelerators – the Impact Centre, UTEST and the Health Innovation Hub (H2i), where Santerre is a co-director. They’ve also received assistance from MaRS Venture Services and the Ontario Bioscience Innovation Organization.

And, while it’s not officially a member, Battiston says Polumiros has participated in investor events organized by JLABS @ Toronto, the first international location of the life sciences incubator created by U.S. health giant Johnson & Johnson.

“The support has been invaluable to myself and Kyle,” Sharifpoor says.

“We’re scientists to the core but we needed that business training and we wouldn’t have gotten it anywhere else – at least not for free, essentially.”

Sharifpoor is now trying to return the favour. At the Ted Rogers Centre, she is hoping to start an entrepreneurship program with the help of H2i to encourage more commercialization of cardiovascular research, an area where she says there are currently too few startups in Canada.

As for Polumiros, Sharifpoor says some potential investors suggested she and Battiston focus on purely cosmetic applications because the bar for regulatory approval may be lower. But she’s adamant breast cancer reconstruction remains the startup’s end goal, adding that, after nearly a decade of research, she knows the ReFilx polymer “like the back of my hand” and is confident in its ability to “help so many people.”

Such commitment is welcome news to cancer survivors like Brambilla Reis, who routinely tells people she’s 25 years old because that’s how long it’s been since she was declared cancer free. If the option had been available, she says she would have jumped at the chance to have undergone a surgery with a better cosmetic outcome.

“For me, if I look back, and I’m going for a lumpectomy and its possible to do this procedure? I think it would be amazing.”

A version of this story originally appeared on U of T News